Biovail Corp. International regulatory update

BVF (Toronto) said U.S. licensee Hoechst-Roussel Pharmaceuticals placed an additional C$7.5 million manufacturing order for BVF’s once-daily version of Diltiazem HCL, used in hypertension. Hoechst-Rou...